Related Experiment Video
Updated: Sep 13, 2026
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
Published on: July 12, 2018
Glypican-3-Targeted PET/MR Identifies MRI-Indeterminate Early Hepatocellular Carcinoma in Cirrhosis
Wenzhu Hu1,2, Mengting Li1,2, Dawei Jiang1,2
1Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Abstract:
Glypican-3 (GPC3) is highly expressed in hepatocellular carcinoma. A 72-year-old man with hepatitis B-related cirrhosis and rising alpha-fetoprotein had a small hepatic nodule on gadoxetic acid-enhanced MRI (EOB-MRI). The nodule enlarged on 3 consecutive EOB-MRI examinations during a 5-month follow-up but remained indeterminate for hepatocellular carcinoma. GPC3-targeted PET/MR showed intense uptake in the lesion and no extrahepatic disease, and hepatectomy confirmed moderately differentiated hepatocellular carcinoma with strong GPC3 expression. This case suggests the potential value of GPC3-targeted PET/MR for clarifying MRI-indeterminate early hepatocellular carcinoma.
